Lupin Strengthens US Presence with Generic Diabetes Drug Launch

has expanded its footprint in the US market by launching generic anti-diabetic tablets following approval from the US Food and Drug Administration (USFDA). The company introduced Dapagliflozin and Metformin Hydrochloride Extended-Release tablets in multiple strengths—5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg, along with a tentative approval for 2.5 mg/1,000 mg. These drugs are bioequivalent to the widely used branded therapy Xigduo XR, ensuring similar efficacy and safety for patients. U.S. Food and Drug Administration approval under the Abbreviated New Drug Application (ANDA) route allows Lupin to tap into the large and competitive US diabetes treatment market, a key revenue driver for global pharma companies. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.